Looming E-Cigarette Regulation Could Shift Cessation Playing Field
This article was originally published in The Tan Sheet
Executive Summary
Approval as smoking cessation products is an expensive option for e-cigarette firms due to the costs of preparing and submitting an NDA to FDA’s drug center. Regulation under the agency’s tobacco center could lead to modified risk status, but might make the NDA route more appealing.
You may also be interested in...
U.K. Packages All Electronic Cigarettes Under Medical Regulation
The U.K. pharma regulator requires all electronic cigarettes to be licensed as nonprescription medicines beginning in 2016, noting concerns about product quality. Meanwhile, FDA considers allowing e-cigarettes to be marketed as nicotine replacement therapy on a case-by-case basis.
E-Cigarette Firm Targets Harm Reduction In Therapeutic Claim
CN Creative’s plan to include harm reduction with smoking cessation in claims for its Nicadex electronic cigarette was key to Advent Life Sciences investing in the firm, which is prepared to ask U.K. regulators for approval this summer before applying in the U.S.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.